CINV Existing and Pipeline Drugs Market to Perceive Substantial Growth During 2014 - 2020
View Report Preview: http://www.transparencymarketresearch.com/cinv-market.html
CINV drugs are administered to patients suffering from vomiting and nausea that occurs as a side effect of chemotherapy. CINV can hinder the progress of patients undergoing chemotherapy, making it very crucial for oncologists to prescribe the right kind of CINV drugs to alleviate the discomfort. Delayed CINV and acute CINV are the two major subtypes of this condition. While the former occurs up to five days after treatment, the latter occurs within 24 hours of a patient receiving chemotherapy.
Based on the major drugs available on the market currently, the report segments the CINV existing drugs market as follows: Akynzeo (netupitant-palonosetron FDC), Aloxi (palonosetron), Zofran Generic (ondansetron), Emend (aprepitant), and Kytril Generic (granisetron). Drugs in the pipeline that are studied in the report include: Rolapitant and SUSTOL (granisetron injection extended release).
Request to view Sample Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=776
It is expected that the incidence rate of cancer will soar 17.1 million by 2020. With a growing prevalence rate of cancer across the world, more and more patients are expected to undergo chemotherapy. This alone will be a high-impact driver for the global CINV drugs market. Studies show that nearly 30% of all people suffering from cancer are advised to undergo chemotherapy. Of these, about 70% to 80% patients suffer from CINV.
In the light of these factors, the CINV existing and pipeline drugs market will receive a boost with the expected launch of new drugs such as SUSTOL (APF-530) and rolapitant. The efficacy of pipeline drugs that are at the clinical study stage has been reported to be higher than that of the current CINV treatment drugs on the market. This will likely lead to physicians prescribing newer drugs more as opposed to existing drugs.
The growth of the CINV drugs market is expected to be hampered to some degree by the patents of two leading drugs – Aloxi and Emend – lapsing. This will cause a dip in the revenue of CINV drugs over the forecast period of the report, which ranges from 2014 to 2020.
Buy CINV Existing and Pipeline Drugs Market Research Report
Studying the market from the regional perspective, the report states that North America was the largest CINV drugs market in 2013 and will remain in this position until 2020. The CINV drugs market in North America will receive a massive boost from rolapitant and SUSTOL. Europe followed North America in terms of CINV drugs revenue in 2013. The alarming increase in cancer cases reported from Asia Pacific and Rest of the World will enable the CINV drugs market to grow vigorously in these markets.
Companies that have secured a competitive edge in the global CINV drugs market are: Helsinn Holding S.A., GlaxoSmithKline plc, Merck & Co., Inc. Heron Therapeutics, Inc., and Tesaro, Inc.
Transparency Market Research (TMR) is a U.S.-based provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.
Transparency Market Research
90 State Street,
NY - 12207
USA - Canada Toll Free 866-552-3453
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release CINV Existing and Pipeline Drugs Market to Perceive Substantial Growth During 2014 - 2020 here
News-ID: 879940 • Views: 111
More Releases from TMR - Research Report
Global Tissue Extraction System Market: Trends and Opportunities 2017 - 2025
Global Tissue Extraction System Market: Overview The global tissue extraction system market is foretold to display an impressive growth rate in the coming years. This could be owing to the need for tissue extraction or biopsy for cancer analysis after the patient has been suspected of carrying the disease. The procedure is extremely vital for diagnosing the disease. Thus, increasing prevalence of carcinogenic agents, compromised immunity levels, and rising incidence of
Neurology Sterile Injectable Market: Growth Factors, Applications, Regional Anal …
Neurology sterile injectables are generally administered to individuals suffering from pain linked to the nerves. Neuropathic pain injections are used to provide relief to these individuals. Neurology sterile injectable block the pain signal from reaching the brain. Neurological sterile injection can be administered at sympathetic nervous system, trigger points, dorsal roots, and peripheral nerves. The most commonly use neurological injectable used for nerve block are steroid injection, opioids, and local
External Fixator Devices Market: Global Survey and Trend Research
External fixator devices are used to stabilize and support long bone open fractures to help the patient carry body’s weight as well as movement. Schanz screws, connecting rods, and clamps are used in case of unipolar external fixators. Circulatory fixators include circular rings, wires, connecting rods, and struts. The external fixator devices provide rigid fixation along with fixed distraction of the fracture fragments. The major advantage of external fixator devices
Anorectal Preparations Market Trends, and Forecast 2017 - 2025
Anorectal preparations are products that contain a combination of an anti-inflammatory agent, or a pain reliever, and a local anesthetic as a suppository, or an ointment. External or internal hemorrhoids are treated by the topical application of anorectal preparations. Hemorrhoids are masses or lumps of tissue in the anus that contain enlarged blood vessels. The formation of hemorrhoids is due to an increase in abdominal pressure. Frequent constipation, which is
More Releases for CINV
CINV Existing and Pipeline Drugs Market: Rising Demand for CINV Drugs Owing to I …
CINV drugs are administered to patients suffering from vomiting and nausea that occurs as a side effect of chemotherapy. CINV can hinder the progress of patients undergoing chemotherapy, making it very crucial for oncologists to prescribe the right kind of CINV drugs to alleviate the discomfort. Delayed CINV and acute CINV are the two major subtypes of this condition. While the former occurs up to five days after treatment, the
Chemotherapy Induced Nausea and Vomiting CINV Drugs Market Excellent Growth Scop …
A new research study from HTF MI with title Global Chemotherapy Induced Nausea and Vomiting ?CINV? Drugs Market Size, Status and Forecast 2025 provides an in-depth assessment of the Chemotherapy Induced Nausea and Vomiting ?CINV? Drugs including key market trends, upcoming technologies, industry drivers, challenges, regulatory policies, key players company profiles and strategies. The research study provides forecasts for Chemotherapy Induced Nausea and Vomiting ?CINV? Drugs investments till 2022. Access
Chemotherapy-induced Nausea and Vomiting (CINV) Treatment Market Analysis And Fo …
According to WHO cancer is one of the most leading causes for death with around 8 million deaths and 14 million new patients in 2012. Chemotherapy, which is received by approximately four million cancer patients each year, is among the most commonly used treatment to fight cancer. However, this mode of treatment has many side effects, an estimate of around 70% - 80% of the patients receiving chemotherapy treatment experience
CINV Existing and Pipeline Drugs Market Projected to Reach US$1.88 bn by 2020
The global chemotherapy induced nausea and vomiting (CINV) drugs market is dominated by players such as Helsinn Holding S. A., Merck & Co. Inc., Tesaro Inc., and Heron Therapeutics, says Transparency Market Research (TMR) in a new study. Helsinn Holding S.A. along with its commercial partner Eisai Co. Ltd. led the overall CINV drugs market by revenue in 2013. The large companies are entering into a number of strategic alliances
Chemotherapy-induced Nausea and Vomiting (CINV) Market Grow $2, 659 Million By 2 …
Nausea and vomiting is one of the common side effects of chemotherapy in the cancer patients. Because of such side effects, the patient population either refuse or deferment the therapeutic chemotherapy treatment for cancer. For More Info, Get Sample: http://bit.ly/2zVmL28 The global Chemotherapy-induced Nausea and Vomiting market was valued at $1,663 million in 2015 and is estimated to reach $2, 659 million by 2022, registering a CAGR of 7.1%
Chemotherapy-induced Nausea and Vomiting (CINV) Market Expected to Reach $2,659 …
Chemotherapy-induced Nausea and Vomiting (CINV) Market report, published by Allied Market Research, forecasts that the global market is expected to garner $2,659 million by 2022, growing at a CAGR of 7.1% during 2016-2022. Access Full Summary At: https://www.alliedmarketresearch.com/cinv-market Increase in adoption of chemotherapeutic drugs is directly linked to the growth of the CINV drugs market. It is estimated that in 2016, approximately 1.6 million new cases of cancer will be diagnosed with